Overview
Interpretation of ECHO and the Path to Diagnostic Certainty in PAH
An interactive ECHO image-based educational activity
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Don’t delay the diagnosis of PAH or overlook high-risk patients who should be screened. Dr. John Ryan approaches this activity through a test first model. The learner is challenged with clinical scenarios via ECHO images and interactive questions, then commentary, recommendations, and strategies are provided by the faculty for application in practice to improve patient outcomes.
This activity is intended for radiologists, pathologists, pulmonologists, cardiologists, and other allied healthcare practitioners managing patients with suspected PAH
The differential diagnosis of PAH is challenging, diagnostic delays are common, and screening of high-risk patient populations is suboptimal, leading to poorer patient outcomes. Clinicians require ongoing education on diagnostic tools and patient populations appropriate for screening to enable earlier detection and intervention. Echocardiography is the most important screening test to determine the probability of PAH, and is one of the first steps of diagnostic testing in patients with history, signs, and symptoms that are suggestive of the disease. Upon completion of this activity, clinicians will be better able to apply echocardiography in their practices to improve their recognition of PAH.
Upon completion of this activity, participants will be able to:
• Discuss the current role of imaging in the diagnosis and management of PAH
• Outline imaging features that suggest a diagnosis of PAH
• Identify high-risk patients that should be referred for PAH diagnostic workup
• Discuss the current role of imaging in the diagnosis and management of PAH
• Outline imaging features that suggest a diagnosis of PAH
• Identify high-risk patients that should be referred for PAH diagnostic workup
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA
Director, Pulmonary Hypertension Comprehensive Care Center
Medical Director, Cardiovascular Medical Unit
University of Utah Hospital
Faculty Director of Cardiology Education
University of Utah School of Medicine
Salt Lake City, UT
Director, Pulmonary Hypertension Comprehensive Care Center
Medical Director, Cardiovascular Medical Unit
University of Utah Hospital
Faculty Director of Cardiology Education
University of Utah School of Medicine
Salt Lake City, UT
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA
Advisory Board: Bayer and Janssen PH
Consultant: Vertex
Speakers Bureau: Bayer, Janssen PH, United Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit,75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
